Physician profile
William R Bennett
NPI 1396791026
$2,004.79
in general payments reported to CMS, 2019-2025
15 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $41.42 · 2022: $180 · 2023: $415 · 2024: $885 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $541.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $244.71 | 2022-2025 | |
| Amgen INC. | $210.97 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.82 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $138.82 | 2020-2024 | Farxiga |
| Boston Scientific Corporation | $128.06 | 2019-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Novo Nordisk INC | $125.00 | 2025 | Ozempic |
| Regeneron Healthcare Solutions, INC. | $117.18 | 2023 | Evkeeza |
| Janssen Pharmaceuticals, INC | $92.68 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $73.85 | 2024-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $57.10 | 2024 | Verquvo, Winrevair |
| Heartflow, INC. | $23.90 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $17.08 | 2024 | Arcalyst |
| Neurocrine Biosciences, INC. | $16.88 | 2022 | |
| Philips North America LLC | $13.47 | 2025 | Mcot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.